A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
Clinical trial NCT03277196 · COMPLETED
Trial details
- NCT number
- NCT03277196
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-16
- Primary completion
- 2023-10-02
- Enrollment
- 86
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.